A non-invasive treatment to protect visual function in early stage diabetic retinopathy patients
PREVIN combines a novel drug delivery method to treat patients with Diabetic Retinopathy (DR) (i.e. blindness in Diabetes patients) with established drugs. This method will improve localized drug delivery with cyclodextrin nanoparticles to the back of the eye for effective, safe, low-cost, preventive and non-invasive treatment of DR. PREVIN, supported by extensive safety and efficacy studies, will be ready for licensing within one year after the end of the project.
2 143 090.00€
Pharmaceutical Products / Drugs